189 related articles for article (PubMed ID: 18519775)
1. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
Bonfils C; Kalita A; Dubay M; Siu LL; Carducci MA; Reid G; Martell RE; Besterman JM; Li Z
Clin Cancer Res; 2008 Jun; 14(11):3441-9. PubMed ID: 18519775
[TBL] [Abstract][Full Text] [Related]
2. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Siu LL; Pili R; Duran I; Messersmith WA; Chen EX; Sullivan R; MacLean M; King S; Brown S; Reid GK; Li Z; Kalita AM; Laille EJ; Besterman JM; Martell RE; Carducci MA
J Clin Oncol; 2008 Apr; 26(12):1940-7. PubMed ID: 18421048
[TBL] [Abstract][Full Text] [Related]
4. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
Le Tourneau C; Siu LL
Expert Opin Investig Drugs; 2008 Aug; 17(8):1247-54. PubMed ID: 18616420
[TBL] [Abstract][Full Text] [Related]
5. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
Boumber Y; Younes A; Garcia-Manero G
Expert Opin Investig Drugs; 2011 Jun; 20(6):823-9. PubMed ID: 21554162
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Garcia-Manero G; Assouline S; Cortes J; Estrov Z; Kantarjian H; Yang H; Newsome WM; Miller WH; Rousseau C; Kalita A; Bonfils C; Dubay M; Patterson TA; Li Z; Besterman JM; Reid G; Laille E; Martell RE; Minden M
Blood; 2008 Aug; 112(4):981-9. PubMed ID: 18495956
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
Blum KA; Advani A; Fernandez L; Van Der Jagt R; Brandwein J; Kambhampati S; Kassis J; Davis M; Bonfils C; Dubay M; Dumouchel J; Drouin M; Lucas DM; Martell RE; Byrd JC
Br J Haematol; 2009 Nov; 147(4):507-14. PubMed ID: 19747365
[TBL] [Abstract][Full Text] [Related]
8. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
[TBL] [Abstract][Full Text] [Related]
9. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
Zhou N; Moradei O; Raeppel S; Leit S; Frechette S; Gaudette F; Paquin I; Bernstein N; Bouchain G; Vaisburg A; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Lu A; Rahil J; MacLeod AR; Li Z; Besterman JM; Delorme D
J Med Chem; 2008 Jul; 51(14):4072-5. PubMed ID: 18570366
[TBL] [Abstract][Full Text] [Related]
11. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
12. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Arts J; King P; Mariën A; Floren W; Beliën A; Janssen L; Pilatte I; Roux B; Decrane L; Gilissen R; Hickson I; Vreys V; Cox E; Bol K; Talloen W; Goris I; Andries L; Du Jardin M; Janicot M; Page M; van Emelen K; Angibaud P
Clin Cancer Res; 2009 Nov; 15(22):6841-51. PubMed ID: 19861438
[TBL] [Abstract][Full Text] [Related]
13. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
15. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Cavasin MA; Demos-Davies K; Horn TR; Walker LA; Lemon DD; Birdsey N; Weiser-Evans MC; Harral J; Irwin DC; Anwar A; Yeager ME; Li M; Watson PA; Nemenoff RA; Buttrick PM; Stenmark KR; McKinsey TA
Circ Res; 2012 Mar; 110(5):739-48. PubMed ID: 22282194
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
El-Khoury V; Moussay E; Janji B; Palissot V; Aouali N; Brons NH; Van Moer K; Pierson S; Van Dyck E; Berchem G
Mol Cancer Ther; 2010 May; 9(5):1349-60. PubMed ID: 20406947
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
18. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
20. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
Cao ZA; Bass KE; Balasubramanian S; Liu L; Schultz B; Verner E; Dai Y; Molina RA; Davis JR; Misialek S; Sendzik M; Orr CJ; Leung L; Callan O; Young P; Dalrymple SA; Buggy JJ
Mol Cancer Ther; 2006 Jul; 5(7):1693-701. PubMed ID: 16891455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]